financial reporting

Kyndryl restated financials citing internal control weaknesses, triggering 55% stock decline and departures of CFO, General Counsel, and Comptroller. SEC investigating disclosure gaps.

Sanofi filed its 2025 annual financial reports with French and U.S. regulators, including governance disclosures and buyback programs, maintaining dual-listing compliance.

Kyndryl faces securities fraud investigation after disclosing audit review of cash management and internal controls. Stock fell 50%; class action deadline set for April 13.